ArticleWorld journal of microbiology & biotechnology2026
Characterization of shrimp waste-based compost and its antifungal efficacy against pathogens causing olive tree decline.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marine waste valorization through composting offers a sustainable strategy to reduce environmental burdens while generating bioactive amendments capable of suppressing soil-borne phytopathogens. This study characterized shrimp waste-based compost and evaluated its in vitro antifungal potential against pathogens causing olive tree decline. Composting for 120 days, a duration selected to encompass the thermophilic, cooling, and maturation phases, produced a mature material with near-neutral pH (7.2 ± 0.3), moderate electrical conductivity (2.1 ± 0.15 mS cm⁻¹), high organic matter (45.2 ± 2.1%), total nitrogen (2.8 ± 0.2%), and a stabilized C/N ratio (18.2), together with humic and fulvic fractions, phenolics, and residual chitinase and protease activities. Culturable antagonistic communities increased markedly during composting, notably Bacillus spp., Pseudomonas spp., Trichoderma spp., and actinomycetes. Compost-derived bacterial isolates (X12, B4, H1, H7, and K) showed broad-spectrum antagonism against major olive decline fungi, including Verticillium dahliae, Fusarium solani, Neofusicoccum sp., Biscogniauxia mediterranea, Macrophomina phaseolina, and Lasiodiplodia theobromae. The strongest inhibition was recorded for isolate X12 against V. dahliae (81.2%) and F. solani (67.8%), and for H7 against V. dahliae (69.86%) and M. phaseolina (61.78%). Molecular identification based on 16 S rRNA gene sequencing assigned the five antagonists to well-known biocontrol taxa: Bacillus subtilis (X12), Bacillus amyloliquefaciens (B4), Pseudomonas putida (H1), Pseudomonas fluorescens (H7), and Bacillus velezensis (K). Compost juice and leachate exhibited strong dose-dependent antifungal activity in vitro, with filter-sterilized preparations reaching up to 99.8% inhibition, while autoclaving reduced activity in a pathogen-dependent manner, indicating contributions from both heat-labile and thermostable compounds. These findings support shrimp waste composting as a promising circular-economy strategy that yields a mature organic amendment and antifungal microbial/chemical fractions; however, greenhouse and field validation are required before disease-management recommendations can be made. This integrated proof-of-concept links chitin-rich marine-waste valorization with olive-decline pathogen suppression and identifies candidate compost-derived microbial fractions for subsequent greenhouse and field validation.
Indexed as
Identifiers
42484900What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.